异源疫苗方案的利益相关者接受度与实施考量
本研究基于文献检索和全球利益相关者访谈开发调查工具,在六个国家开展在线调查和关键知情人访谈,覆盖政策制定者、监管者和实施者。研究探索对异源疫苗方案(异源初免-加强)的未来接受度和接种意愿,并识别实施相关益处与挑战。结果显示青少年/成人无现有疫苗可用疾病的免疫预防引入潜力最高,主要保留意见涉及后勤、记录保存和受种者依从性。
要点
- 青少年/成人无现有疫苗可用疾病的异源方案引入潜力最高。
- 主要保留意见涉及后勤、记录保存和受种者依从性。
- 儿童常规免疫引入需能产生更强更持久免疫应答才被视为可行。
核心结论
- 受访者认为异源疫苗方案在青少年/成人无现有疫苗可用疾病的免疫预防中引入潜力最高。
- 儿童常规免疫引入异源方案若可产生更强更持久免疫应答则被视为可行。
- 疫情暴发准备或后引入异源方案评价较低,因紧急后勤困难和保护起效滞后。
研究设计与样本
- 基于文献检索和全球利益相关者探索性访谈开发调查工具。
- 在六个国家开展在线调查和关键知情人访谈,覆盖国家和地方层面政策制定者、监管者和实施者。
主要发现
- 四种引入情景中,青少年/成人无现有疫苗可用疾病的免疫预防被评最高引入潜力。
- 大多数保留意见与后勤、记录保存和受种者依从性相关。
- 儿童常规免疫引入异源方案若可产生更强更持久免疫应答则视为可行。
- 疫情暴发准备或后引入评价较低,受访者强调紧急后勤困难和保护起效滞后。
临床怎么用
- 在评估异源疫苗方案引入时需重点考虑后勤、记录保存和受种者依从性。
- 儿童常规免疫引入需评估其是否能产生更强更持久免疫应答。
- 疫情相关引入需权衡紧急后勤困难和保护起效滞后问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heterologous vaccine regimens deliver antigens through different vaccine components or vector types at sequential time points. Clinical development shows promising results and several candidates may be progressing to licensure in the coming years. This study aimed at exploring future acceptance and uptake of such regimens (also called heterologous prime-boost) and to identify implementation-associated benefits and challenges. Survey tools were developed based on findings from a previous literature search shared with the study team, and exploratory interviews with global stakeholders. An online survey and key informant interviews in six countries were conducted with stakeholders at national and sub-national level, including policy-makers, regulators and implementers. The interview guide and the online survey covered: (a) awareness of, and knowledge about, heterologous vaccine regimens; (b) rating of regimen-associated perceived benefits and challenges; (c) anticipation of possible challenges in relation to four hypothetical introduction scenarios; (d) potential acceptance benefits and challenges at the policy, health facility and recipient level. Sixty-two interviews were conducted at national level. The online survey was completed by 50 participants. Across the four introduction scenarios, respondents considered the highest potential for the introduction of heterologous regimens for immunoprophylaxis was among adolescents/adults for diseases against which no vaccines are currently available. Most reservations were related to logistics, record keeping, and recipient compliance. Adding a new heterologous vaccine regimen to the routine immunization calendar for children was considered feasible if it could generate an increased and longer-term immune response. Introduction in preparation of or following a disease outbreak was considered less favourably, with respondents stressing the difficulty of logistics in emergency situations, and the potential lag in the onset of protection. The recent approval of the first heterologous vaccine regimen for the prevention of Ebola Virus Disease will soon bring new light to the topic.
引用
- Greter H, Ivol S, Oriol Mathieu V, et al. Heterologous vaccine regimen: Stakeholder acceptance and implementation considerations. Vaccine. 2020. PMID: 33342636. doi:10.1016/j.vaccine.2020.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。